Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HCMSpliceAOC

Financiado

Cerrado

Molecular design and application of splice-switching antibody-oligonucleotide co...

Molecular design and application of splice-switching antibody-oligonucleotide conjugate for hypertrophic cardiomyopathy-related MYBPC3 splice modulation. Familial hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease and is predominately caused by mutations in genes that encode proteins associated with cardiac sarcomeres, the functional unit critical for basi... ver más

31/05/2025

iMM

157K€

Presupuesto del proyecto: 157K€

Líder del proyecto

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-05-15

HORIZON-WIDERA-2022-TALENTS-04-01: Fostering balanced brain circulatio... ExpectedOutcome:This action will build on the MSCA Postdoctoral Fellowships 2022 action (HORIZON-MSC...

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

iMM

156.78K€ | Lider

MDC

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

GEREMY Gene Therapy for treatment of rare inherited Arrhythmogenic... 7M€ Cerrado

SAF2012-31451 MODULACION DEL SPLICING ALTERNATIVO EN EL CORAZON INFARTADO 164K€ Cerrado

Edit-hCOs Precise Genome Editing to Correct Cardiomyopathies in Human... 189K€ Cerrado

CARDIOSPLICE A systems and targeted approach to alternative splicing in t... 1M€ Cerrado

HeartGenes Next Generation Gene Therapy for the Treatment of Chronic My... 3M€ Cerrado

CardioReGenix CardioReGenix Development of Next Generation Gene Therapies... 15M€ Cerrado

Duración del proyecto: 24 meses Fecha Inicio: 2023-05-15
Fecha Fin: 2025-05-31

Líder del proyecto

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 157K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Familial hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease and is predominately caused by mutations in genes that encode proteins associated with cardiac sarcomeres, the functional unit critical for basic contractile heart function. Nearly two-thirds of individuals with HCM experience mild to no symptoms, whereas the remaining one-third experience dyspnea, chest pain, or arrythmias that can progress into heart failure, causing sudden cardiac death, particularly in young competitive athletes. Current strategies to treat HCM include invasive procedures such as septal or left ventricular reduction therapies or cardiac implantation. Such methods are not curative, but rather aimed to treat symptoms and not the pathophysiological cause of the disease, thus highlighting the importance of new molecular therapies that can prevent HCM. One potential method to correct HCM mutations is through the use of antisense oligonucleotides (ASOs), short polymeric nucleic acid biomolecules, that can correct aberrant RNA splicing, a fundamental biological process for gene expression, by binding to pre-mRNA splice sites and block recognition by the spliceosome. However, delivery of ASOs to cardiac cell models, including cardiomyocytes differentiated from human induced pluripotent stem cells (iPSC-CMs), remains to be one of the biggest challenges in ASO efficacy. Herein, this project proposes to design and test the effects of chemically-modified, splice-switching antisense oligonucleotides conjugated to an antibody, an antibody-oligonucleotide conjugate (AOC), using a unique traceless linker strategy that has the potential to not only treat splicing defects in HCM, but also provide proof-of-concept of improved cell delivery of ASOs. AOCs will be tested in iPSC-CMs bearing cryptic splice mutations in MYBPC3 (myosin binding protein C), a gene whose mutations are commonly associated with HCM.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores